ABBV · Categories · M&A
ABBV - Mergers and acquisitions
AbbVie Inc. (ABBV) mergers and acquisitions - real-time wire coverage filtered to M&A only.
Recent M&A for ABBV
- AbbVie to Acquire Aliada Therapeutics, Strengthening Focus in Alzheimer's Disease and Neuroscience PipelineAliada's lead compound, ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, is a potential best-in-class therapy for Alzheimer's diseaseAcquisition also allows AbbVie to utilize Aliada's novel blood-brain barrier (BBB)-crossing technology to enhance discovery and development efforts across neuroscienceNORTH CHICAGO, Ill. and BOSTON, Oct. 28, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) and Aliada Therapeutics today announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. Aliada's lead investigational asse
- AbbVie Acquires Celsius TherapeuticsCelsius' CEL383 is a potential first-in-class anti-Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) antibody for the treatment of inflammatory bowel disease (IBD)NORTH CHICAGO, Ill., June 27, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced today the acquisition of Celsius Therapeutics, Inc. ("Celsius"), a privately held biotechnology company pioneering new therapies for patients with inflammatory disease. Celsius' lead investigational asset is CEL383, a potential first-in-class anti-TREM1 antibody that has completed a Phase 1 clinical study for the treatment of IBD. TREM1 has been identified as a key disease driver gene in IBD, where it is expressed on inflammatory monocytes and ne
- AbbVie Exercises Exclusive Right to Acquire Mitokinin, Further Strengthening Neuroscience Pipeline- Mitokinin's lead compound, a selective PINK1 activator, is designed to address mitochondrial dysfunction, which plays a key role in the pathogenesis of Parkinson's disease - Activation of PINK1 remediates mitochondrial damage and restores mitochondrial function NORTH CHICAGO, Ill., Oct. 5, 2023 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced today that it has exercised its exclusive right and completed the acquisition of Mitokinin, a discovery-stage biotechnology company developing a potentially first-in-class disease-modifying treatment for Parkinson's Disease (PD). Mitokinin's lead compound, a selective PINK1 activator, is designed to address mitochondrial dysfunction that is believed to
- AbbVie Acquires DJS Antibodies, Further Strengthening Immunology Pipeline-- DJS Antibodies' DJS-002 is a potential first-in-class antibody directed to LPAR1, currently in investigational preclinical studies for the treatment of Idiopathic Pulmonary Fibrosis and other fibrotic diseases -- The company's proprietary HEPTAD platform will extend AbbVie's current discovery research capabilities by generating potential novel antibodies against difficult-to-drug protein targets in immunology and beyond NORTH CHICAGO, Ill., Oct. 20, 2022 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced the acquisition of DJS Antibodies Ltd ("DJS"), a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target difficult-to-drug di
- AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience PortfolioNORTH CHICAGO, Ill., March 1, 2022 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. The mechanism is currently being evaluated for the potential treatment of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders, such as Alzheimer's disease and major depressive disorder. "There is a major unmet need for new therapies that can help improve cognitive fun
- Healis Therapeutics acquires ownership of key botulinum toxin patentWASHINGTON, Feb. 10, 2022 /PRNewswire/ -- Healis Therapeutics, a privately held biotechnology company, today announces its ownership of a key botulinum toxin patent from AbbVie (NYSE:ABBV). After clinically significant results in early trials, Allergan acquired the rights to develop botulinum toxin for depression in 2013. Allergan completed a Phase II study in 2017 and announced plans for Phase III. AbbVie assumed ownership through its 2020 acquisition of Allergan. Today, Healis Therapeutics takes over the exclusive license from AbbVie to develop botulinum toxin as a potentia
- Psychedelics are Gaining Traction as Therapies and MedicinesNEW YORK, Feb. 11, 2021 /PRNewswire/ -- The psychedelic drug market continues to follow a similar path to the cannabis segment. It is now slowly getting more attention from investors as the stigma surrounding psychedelic drugs fades. In particular, the growing acceptance of using psychedelics to treat various mental disorders such as depression is actually fueling market growth. Recently, a total of three breakthrough therapy designations have been awarded by the FDA to psychedelic assisted therapy clinical trials for psilocybin and MDMA. The designations could potentially help shorten the development timelines of these psychedelic focused clinical trials, positively affecting patients su
- Researchers Seek to Better Understand Psychedelics' Role in New TherapiesNEW YORK, Jan. 12, 2021 /PRNewswire/ -- Psychedelics are slowly becoming more acceptable as a legitimate treatment option for various anxiety and depression related mental illnesses. Depression is one of the most common chronic neurological disorders in modern society. It is estimated that over 250 million people suffer from some form of depression around the world. And, according to a report by Research and Markets, the U.S. reported a sharp increase (~20%) in the number of prescriptions for antidepressants and anti-anxiety drugs during the global lockdown enforced to curb the spread of the pandemic. Furthermore, the World Health Organization indicated that the major barriers to effectiv